Log in

Relevant bibliographies by topics / Anticancer chemotherapy / Journal articles

To see the other types of publications on this topic, follow the link: Anticancer chemotherapy.

Journal articles on the topic 'Anticancer chemotherapy'

Author: Grafiati

Published: 28 June 2021

Last updated: 1 February 2022

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic 'Anticancer chemotherapy.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

Hayashi, S., S. Maruoka, N. Takahashi, and S. Hashimoto. "Carotidynia after anticancer chemotherapy." Singapore Medical Journal 55, no. 09 (September 2014): e142-e144. http://dx.doi.org/10.11622/smedj.2014127.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Kvolik, S., L. Glavas-Obrovac, K. Sakic, D. Margaretic, and I. Karner. "Anaesthetic implications of anticancer chemotherapy." European Journal of Anaesthesiology 20, no. 11 (July 11, 2005): 859–71. http://dx.doi.org/10.1017/s026502150300139x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

Kvolik, S., L. Glavas-Obrovac, K. Sakic, D. Margaretic, and I. Karner. "Anaesthetic implications of anticancer chemotherapy." European Journal of Anaesthesiology 20, no. 11 (November 2003): 859–71. http://dx.doi.org/10.1097/00003643-200311000-00002.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

F. Goncalves, R., G. Kriechammer, and M. P.M. Marques. "MGBG in Combined Anticancer Chemotherapy." Letters in Drug Design & Discovery 8, no. 10 (December 1, 2011): 897–903. http://dx.doi.org/10.2174/157018011797655197.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

Kratz, Felix, Ivonne A Müller, Claudia Ryppa, and André Warnecke. "Prodrug Strategies in Anticancer Chemotherapy." ChemMedChem 3, no. 1 (January 11, 2008): 20–53. http://dx.doi.org/10.1002/cmdc.200700159.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

Kris, M. G., Fausto Roila, Pieter H. M. De Mulder, and Michel Marty. "Delayed emesis following anticancer chemotherapy." Supportive Care in Cancer 6, no. 3 (April 27, 1998): 228–32. http://dx.doi.org/10.1007/s005200050158.

Full text

APA, Harvard, Vancouver, ISO, and other styles

7

Kris, M. G., K. M. W. Pisters, and L. Hinkley. "Delayed emesis following anticancer chemotherapy." Supportive Care in Cancer 2, no. 5 (September 1994): 297–300. http://dx.doi.org/10.1007/bf00365581.

Full text

APA, Harvard, Vancouver, ISO, and other styles

8

Hennes, Emily R., Michael Reed, Mary Mably, Jason Jared, Jason J. Bergsbaken, Dustin Deming, Natalie Callander, and Ruth O’Regan. "Implementation of a chemotherapy stewardship process." American Journal of Health-System Pharmacy 77, no. 15 (July 4, 2020): 1243–48. http://dx.doi.org/10.1093/ajhp/zxaa157.

Full text

Abstract:

Abstract Purpose To design and implement a chemotherapy stewardship process to optimize the location of chemotherapy administration in an effort to decrease the number of inappropriate inpatient anticancer regimen administrations and decrease institutional costs associated with inpatient administration. Summary As the costs of anticancer agents continue to rise, it is crucial that multidisciplinary efforts are aimed at managing anticancer medication utilization; this is especially important for high-cost medications, medications whose use requires increased monitoring due to safety concerns, and medications that do not exert effects quickly and, as such, can be more appropriately administered in the outpatient setting. It is imperative that pharmacists play a role in managing chemotherapy medication utilization, as pharmacists provide expertise in formulary management, a vast knowledge of financial impact and reimbursement processes, and clinical knowledge that can help predict the expected effectiveness and adverse effects of each anticancer regimen. Our institution sought to develop and implement a multidisciplinary chemotherapy stewardship program targeting the optimization of site of anticancer agent administration with a goal of decreasing both cost and inappropriate utilization of high-cost, high-risk anticancer agents. Conclusion Implementation of a chemotherapy stewardship service may decrease the number of inappropriate inpatient anticancer regimen administrations and decrease inpatient resource use, thereby decreasing costs to institutions. The concept of a chemotherapy stewardship process was well received by multidisciplinary healthcare colleagues, and a collaborative approach should be used to design and implement such processes.

APA, Harvard, Vancouver, ISO, and other styles

9

Ben Kridis, W., A. Khanfir, and M. Frikha. "ACUTE PANCREATITIS INDUCED BY ANTICANCER CHEMOTHERAPY." Acta Clinica Belgica 68, no. 4 (July 2013): 309–10. http://dx.doi.org/10.2143/acb.3351.

Full text

APA, Harvard, Vancouver, ISO, and other styles

10

Ma, Yuting, Oliver Kepp, François Ghiringhelli, Lionel Apetoh, Laetitia Aymeric, Clara Locher, Antoine Tesniere, et al. "Chemotherapy and radiotherapy: Cryptic anticancer vaccines." Seminars in Immunology 22, no. 3 (June 2010): 113–24. http://dx.doi.org/10.1016/j.smim.2010.03.001.

Full text

APA, Harvard, Vancouver, ISO, and other styles

11

Popruzhenko, Т. V., and S. P. Boris. "Salivation in children during anticancer chemotherapy." Stomatologiya 95, no. 2 (2016): 30. http://dx.doi.org/10.17116/stomat201695230-33.

Full text

APA, Harvard, Vancouver, ISO, and other styles

12

Bacherikov, V. A. "ANTIFOLATES FOR ANTICANCER CHEMOTHERAPY. PART IІ." Odesa National University Herald. Chemistry 18, no. 4(48) (January 30, 2015): 26. http://dx.doi.org/10.18524/2304-0947.2013.4(48).37019.

Full text

APA, Harvard, Vancouver, ISO, and other styles

13

Locher, Clara, Rosa Conforti, Laetitia Aymeric, Yuting Ma, Takahiro Yamazaki, Sylvie Rusakiewicz, Antoine Tesnière, et al. "Desirable cell death during anticancer chemotherapy." Annals of the New York Academy of Sciences 1209, no. 1 (October 2010): 99–108. http://dx.doi.org/10.1111/j.1749-6632.2010.05763.x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

14

Kumagai, Kazuhide, Kouji Shimizu, Kouki Masuo, Kennichi Yamagata, and Takayuki Tanaka. "Anticancer Effects ofPreoperative Chemotherapy onColorectal Carcinoma." Digestive Surgery 15, no. 4 (1998): 337–41. http://dx.doi.org/10.1159/000018649.

Full text

APA, Harvard, Vancouver, ISO, and other styles

15

Hryvkova, L. V. "Anticancer chemotherapy with high-dose methotrexate." Practical oncology 4, no. 1 (May 17, 2021): 30–38. http://dx.doi.org/10.22141/2663-3272.4.1.2021.229869.

Full text

Abstract:

The literature review is devoted to the use of high doses of methotrexate in oncology. There is a brief historical overview of the use of methotrexate for the treatment of malignant neoplasms; the main mechanism of its cytotoxic effect on tumor cells, the development of resistance to methotrexate, the main indications for the use of high doses of methotrexate and the main side effects of this treatment are considered. The review details the results of using high doses of methotrexate in the treatment of patients with osteosarcoma, non-Hodgkin’s lymphomas, located mainly in the central nervous system, and acute lymphoblastic leukemia.

APA, Harvard, Vancouver, ISO, and other styles

16

Yu, Yue, Masahiro Nishikawa, Ming Liu, Takahiro Tei, Sunil C. Kaul, Renu Wadhawa, Minfang Zhang, Junko Takahashi, and Eijiro Miyako. "Self-assembled nanodiamond supraparticles for anticancer chemotherapy." Nanoscale 10, no. 19 (2018): 8969–78. http://dx.doi.org/10.1039/c8nr00641e.

Full text

Abstract:

Chemically functionalized nanodiamonds (NDs) were transformed into supraparticle (SP) nanoclusters via self-assembly. The ND–SP nanoclusters were biocompatible and internalized by cancer cells, and markedly enhanced anticancer drug efficacy compared to conventional nanomedicines.

APA, Harvard, Vancouver, ISO, and other styles

17

Shurin, Michael R. "Dual role of immunomodulation by anticancer chemotherapy." Nature Medicine 19, no. 1 (January 2013): 20–22. http://dx.doi.org/10.1038/nm.3045.

Full text

APA, Harvard, Vancouver, ISO, and other styles

18

Ben-Aharon, Irit, and Ruth Shalgi. "What lies behind chemotherapy-induced ovarian toxicity?" REPRODUCTION 144, no. 2 (August 2012): 153–63. http://dx.doi.org/10.1530/rep-12-0121.

Full text

Abstract:

Seminal advances in anticancer therapy as well as supportive care strategies have led to improved survival rates, posing an emphasis on preserving an optimum quality of life after cancer treatment. This recognition has paved the way to an increasing research of long-term side effects, both clinical and preclinical and to an ongoing design of a supportive care system to evaluate and treat long-term adverse effects of anticancer treatments, including the impact on fertility. As with many adverse effects induced by anticancer treatments, the literature comprised mostly clinical data with regard to chemotherapy-induced gonadotoxicity, while understanding of the biological mechanism is lagging. The impact of anticancer treatments on female fertility depends on the women's age at the time of treatment, the chemotherapy protocol, the duration, and total cumulative dose administered. Several suggested mechanisms that underlie chemotherapy-induced gonadotoxicity have been described. This review illustrates the clinical evidence, as well as its supportive preclinical studies, while proceeding from the ‘bedside to the bench work’ and provides an insight to what lies behind chemotherapy-induced gonadotoxicity.

APA, Harvard, Vancouver, ISO, and other styles

19

Shih, Ya-Chen Tina, Fabrice Smieliauskas, Daniel M. Geynisman, Ronan J. Kelly, and Thomas J. Smith. "Trends in the Cost and Use of Targeted Cancer Therapies for the Privately Insured Nonelderly: 2001 to 2011." Journal of Clinical Oncology 33, no. 19 (July 1, 2015): 2190–96. http://dx.doi.org/10.1200/jco.2014.58.2320.

Full text

Abstract:

Purpose This study sought to define and identify drivers of trends in cost and use of targeted therapeutics among privately insured nonelderly patients with cancer receiving chemotherapy between 2001 and 2011. Methods We classified oncology drugs as targeted oral anticancer medications, targeted intravenous anticancer medications, and all others. Using the LifeLink Health Plan Claims Database, we studied and disaggregated trends in use and in insurance and out-of-pocket payments per patient per month and during the first year of chemotherapy. Results We found a large increase in the use of targeted intravenous anticancer medications and a gradual increase in targeted oral anticancer medications; targeted therapies accounted for 63% of all chemotherapy expenditures in 2011. Insurance payments per patient per month and in the first year of chemotherapy for targeted oral anticancer medications more than doubled in 10 years, surpassing payments for targeted intravenous anticancer medications, which remained fairly constant throughout. Substitution toward targeted therapies and growth in drug prices both at launch and postlaunch contributed to payer spending growth. Out-of-pocket spending for targeted oral anticancer medications was ≤ half of the amount for targeted intravenous anticancer medications. Conclusion Targeted therapies now dominate anticancer drug spending. More aggressive management of pharmacy benefits for targeted oral anticancer medications and payment reform for injectable drugs hold promise. Restraining the rapid rise in spending will require more than current oral drug parity laws, such as value-based insurance that makes the benefits and costs transparent and involves the patient directly in the choice of treatment.

APA, Harvard, Vancouver, ISO, and other styles

20

Li, Fan, Xinqing Fu, Qingqing Huo, and Wantao Chen. "Research Progress on the Nano-Delivery Systems of Antitumor Drugs." Nano LIFE 10, no. 01n02 (March 2020): 2040006. http://dx.doi.org/10.1142/s1793984420400061.

Full text

Abstract:

To date, chemotherapy, the main treatment for malignant tumors, still fails to provide ideal therapeutic efficacy, which is deeply rooted in various physiological barriers, either temporal or spatial, to the delivering of anticancer drugs to solid tumor sites during chemotherapy. In the meantime, the therapeutic efficacy of anticancer drugs is affected by inherent cancer characteristics, drug transport, cellular uptake and other complex interactions. Recently, advances have been constantly achieved on nanoscale drug delivery systems (NDDSs) for anticancer drug delivery, driven by their excellent stability and effectiveness in improving water solubility of anticancer drugs, prolonging systemic circulation time, reducing side effects and improving anticancer effects. This paper presents an overview of the current research status and challenges in applying NDDSs to anticancer drug delivery.

APA, Harvard, Vancouver, ISO, and other styles

21

Xu, Tengyan, Chunhui Liang, Debin Zheng, Xiaorong Yan, Yaoxia Chen, Yumiao Chen, Xinxin Li, Yang Shi, Ling Wang, and Zhimou Yang. "Nuclear delivery of dual anticancer drug-based nanomedicine constructed by cisplatinum-induced peptide self-assembly." Nanoscale 12, no. 28 (2020): 15275–82. http://dx.doi.org/10.1039/d0nr00143k.

Full text

APA, Harvard, Vancouver, ISO, and other styles

22

Tiligada, E. "Chemotherapy: induction of stress responses." Endocrine-Related Cancer 13, Supplement_1 (December 2006): S115—S124. http://dx.doi.org/10.1677/erc.1.01272.

Full text

Abstract:

Eukaryotic cells, from yeast to mammals, respond and adapt to environmental and microenvironmental stressors by evolutionary conserved multicomponent endogenous systems that utilise a network of signal transduction pathways to regulate the adaptive and protective phenotype. The balance between cell survival and cell death is decisive for sensitivity or resistance to DNA-damaging chemotherapeutic agents. Anticancer drugs may themselves act as stressors to induce adaptive signals that could limit their clinical value. Related research has been focused on the modulation of the expression and function of the heat shock proteins, the unfolded protein response, the mechanisms of subcellular translocation of signalling components, the genomic and non-genomic actions of drugs and endogenous functional components like hormonal pathways, the input of inflammation and alterations in the microenvironmental milieu and on the control of the cell cycle and proliferation. The outcome seems to be driven by the first-line responses that support cellular integrity and by specific mechanisms that depend on the type of cell and the nature, and duration and severity of the noxious stimulus. Data obtained from experimental organisms like the yeast have added valuable information on the basic conservation in cellular stress-related processes in eukaryotes and on the consequences that may accompany the adaptive and protective phenotype during the stress response to anticancer agents. Understanding the complex molecular pathways mediating these processes has started to contribute to the reevaluation of the current therapeutic regiments and to revolutionise the approaches for improved anticancer therapy.

APA, Harvard, Vancouver, ISO, and other styles

23

Kaufmann, S. H., and R. Hancock. "Topoisomerase II as a target for anticancer chemotherapy." Acta Biochimica Polonica 42, no. 4 (December 31, 1995): 381–93. http://dx.doi.org/10.18388/abp.1995_4892.

Full text

Abstract:

Type II DNA topoisomerases are required for the segregation of genomic DNA at cell division in prokaryotic and eukaryotic cells, and inhibitors of these enzymes are potential cytotoxic agents in both prokaryotes and eukaryotes. The bacterial member of the topoisomerase II family, DNA gyrase, and the chemotherapeutic agents which target it are the subject of a recent review (Maxwell, A. et al., 1993, in Molecular Biology of DNA Topoisomerases, Andoh, T. et al., eds., pp. 21-30, CRC Press, Boca Raton). Here we present an overview of current knowledge of eukaryotic topoisomerase II and the anticancer agents which target this enzyme, focussing predominantly on new observations and recent reports and reviews.

APA, Harvard, Vancouver, ISO, and other styles

24

Bansal, DivyaBhargava, Dipankar Bhadra, Umesh Gupta, and NK Jain. "PEGylated methotrexate based micellar conjugates for anticancer chemotherapy." Asian Journal of Pharmaceutics 9, no. 1 (2015): 60. http://dx.doi.org/10.4103/0973-8398.150042.

Full text

APA, Harvard, Vancouver, ISO, and other styles

25

Klinkert, M., and V. Heussler. "The Use of Anticancer Drugs in Antiparasitic Chemotherapy." Mini-Reviews in Medicinal Chemistry 6, no. 2 (February 1, 2006): 131–43. http://dx.doi.org/10.2174/138955706775475939.

Full text

APA, Harvard, Vancouver, ISO, and other styles

26

Wang, Xiaoyong, and Zijian Guo. "The Role of Sulfur in Platinum Anticancer Chemotherapy." Anti-Cancer Agents in Medicinal Chemistry 7, no. 1 (January 1, 2007): 19–34. http://dx.doi.org/10.2174/187152007779314062.

Full text

APA, Harvard, Vancouver, ISO, and other styles

27

Ploylearmsaeng, Su-arpa, Uwe Fuhr, and Alexander Jetter. "How may Anticancer Chemotherapy with Fluorouracil be Individualised?" Clinical Pharmacokinetics 45, no. 6 (2006): 567–92. http://dx.doi.org/10.2165/00003088-200645060-00002.

Full text

APA, Harvard, Vancouver, ISO, and other styles

28

Maeta, Michio, Kiyoaki Mizusawa, and Shigemasa Koga. "Induction of diffuse necrotizing enterocolitis by anticancer chemotherapy." Gastroenterologia Japonica 22, no. 3 (June 1987): 370–73. http://dx.doi.org/10.1007/bf02774263.

Full text

APA, Harvard, Vancouver, ISO, and other styles

29

Han, Xiang Y., and Jeffrey J. Tarrand. "Moraxella osloensisBlood and Catheter Infections During Anticancer Chemotherapy." American Journal of Clinical Pathology 121, no. 4 (April 2004): 581–87. http://dx.doi.org/10.1309/qbb3avcmgwa3k1xk.

Full text

APA, Harvard, Vancouver, ISO, and other styles

30

Shi, Huayun, Cinzia Imberti, and Peter J. Sadler. "Diazido platinum(iv) complexes for photoactivated anticancer chemotherapy." Inorganic Chemistry Frontiers 6, no. 7 (2019): 1623–38. http://dx.doi.org/10.1039/c9qi00288j.

Full text

APA, Harvard, Vancouver, ISO, and other styles

31

Zaffaroni, N., G. Fiorentini, and U. De Giorgi. "Hyperthermia and hypoxia: new developments in anticancer chemotherapy." European Journal of Surgical Oncology (EJSO) 27, no. 4 (June 2001): 340–42. http://dx.doi.org/10.1053/ejso.2000.1040.

Full text

APA, Harvard, Vancouver, ISO, and other styles

32

Robaey, Philippe, Maja Krajinovic, Sophie Marcoux, and Albert Moghrabi. "Pharmacogenetics of the neurodevelopmental impact of anticancer chemotherapy." Developmental Disabilities Research Reviews 14, no. 3 (2008): 211–20. http://dx.doi.org/10.1002/ddrr.29.

Full text

APA, Harvard, Vancouver, ISO, and other styles

33

Zunino, Barbara, and Jean-Ehrland Ricci. "Hyperthermic intra-peritoneal chemotherapy and anticancer immune response." OncoImmunology 5, no. 1 (July 15, 2015): e1060392. http://dx.doi.org/10.1080/2162402x.2015.1060392.

Full text

APA, Harvard, Vancouver, ISO, and other styles

34

Fulda, S., and K.-M. Debatin. "Extrinsic versus intrinsic apoptosis pathways in anticancer chemotherapy." Oncogene 25, no. 34 (August 2006): 4798–811. http://dx.doi.org/10.1038/sj.onc.1209608.

Full text

APA, Harvard, Vancouver, ISO, and other styles

35

Costantini, P. "Mitochondrion as a Novel Target of Anticancer Chemotherapy." Journal of the National Cancer Institute 92, no. 13 (July 5, 2000): 1042–53. http://dx.doi.org/10.1093/jnci/92.13.1042.

Full text

APA, Harvard, Vancouver, ISO, and other styles

36

Potanovich, Lisa M., Katherine M. W. Pisters, Mark G. Kris, Leslie B. Tyson, Rebecca A. Clark, Lorraine Baltzer, and Richard J. Gralla. "Midazolam in patients receiving anticancer chemotherapy and antiemetics." Journal of Pain and Symptom Management 8, no. 8 (November 1993): 519–24. http://dx.doi.org/10.1016/0885-3924(93)90080-f.

Full text

APA, Harvard, Vancouver, ISO, and other styles

37

Ranchon, Florence, Céline Moch, Benoît You, Gilles Salles, Vérane Schwiertz, Nicolas Vantard, Emilie Franchon, et al. "Predictors of prescription errors involving anticancer chemotherapy agents." European Journal of Cancer 48, no. 8 (May 2012): 1192–99. http://dx.doi.org/10.1016/j.ejca.2011.12.031.

Full text

APA, Harvard, Vancouver, ISO, and other styles

38

Mazzei, Teresita, and Enrico Mini. "Clinical application of biochemical modulation in anticancer chemotherapy." Pharmacological Research 26 (September 1992): 225. http://dx.doi.org/10.1016/1043-6618(92)91160-i.

Full text

APA, Harvard, Vancouver, ISO, and other styles

39

Basilotta, Rossella, Deborah Mannino, Alessia Filippone, Giovanna Casili, Angela Prestifilippo, Lorenzo Colarossi, Gabriele Raciti, Emanuela Esposito, and Michela Campolo. "Role of Calixarene in Chemotherapy Delivery Strategies." Molecules 26, no. 13 (June 29, 2021): 3963. http://dx.doi.org/10.3390/molecules26133963.

Full text

Abstract:

Since cancer is a multifactorial disease with a high mortality rate, the study of new therapeutic strategies is one of the main objectives in modern research. Numerous chemotherapeutic agents, although widely used, have the disadvantage of being not very soluble in water or selective towards cancerous cells, with consequent side effects. Therefore, in recent years, a greater interest has emerged in innovative drug delivery systems (DDSs) such as calixarene, a third-generation supramolecular compound. Calixarene and its water-soluble derivatives show good biocompatibility and have low cytotoxicity. Thanks to their chemical–physical characteristics, calixarenes can be easily functionalized, and by itself can encapsulate host molecules forming nanostructures capable of releasing drugs in a controlled way. The encapsulation of anticancer drugs in a calixarene derivate improves their bioavailability and efficacy. Thus, the use of calixarenes as carriers of anticancer drugs could reduce their side effects and increase their affinity towards the target. This review summarizes the numerous research advances regarding the development of calixarene nanoparticles capable of encapsulating various anticancer drugs.

APA, Harvard, Vancouver, ISO, and other styles

40

Cao, Shuwen, Chunhao Lin, Shunung Liang, Chee Hwee Tan, Phei Er Saw, and Xiaoding Xu. "Enhancing Chemotherapy by RNA Interference." BIO Integration 1, no. 2 (September 7, 2020): 64–81. http://dx.doi.org/10.15212/bioi-2020-0003.

Full text

Abstract:

Abstract Small interfering RNA (siRNA) has shown tremendous potential for treating human diseases in the past decades. siRNA can selectively silence a pathological pathway through the targeting and degradation of a specific mRNA, significantly reducing the off-target side effects of anticancer drugs. However, the poor pharmacokinetics of RNA significantly restricted the clinical use of RNAi technology. In this review, we examine in-depth the siRNA therapeutics currently in preclinical and clinical trials, multiple challenges faced in siRNA therapy, feasibility of siRNA treatment with anticancer drugs in combined with siRNA in nanoparticles or modified to be parental drugs, sequential therapy of siRNA treatment prior to drug treatment with siRNA and drugs loaded in nanoparticles. We focused on the combinatorial activation of apoptosis by different pathways, namely Bcl-2, survivin, and Pgp protein. Taken together, this review would serve to establish the pathway of effective and efficient combination therapy of siRNA and drugs as a new strategy.

APA, Harvard, Vancouver, ISO, and other styles

41

Maor, Y., and S. Malnick. "Liver Injury Induced by Anticancer Chemotherapy and Radiation Therapy." International Journal of Hepatology 2013 (2013): 1–8. http://dx.doi.org/10.1155/2013/815105.

Full text

Abstract:

Cytotoxic chemotherapy prolongs survival of patients with advanced and metastatic tumors. This is, however, a double-edged sword with many adverse effects. Since the liver has a rich blood supply and plays an active role in the metabolism of medications, it is not surprising that there can be hepatic injury related to chemotherapy. In addition, radioembolization may affect the parenchyma of normal and cirrhotic livers. We review chemotherapy-associated liver injury in patients with colorectal liver metastases, including downsizing chemotherapy and neoadjuvant chemotherapy. We discuss the mechanism of the hepatic injury, secondary to reactive oxygen species, and the spectrum of hepatic injury including, steatosis, steatohepatitis, hepatic sinusoidal injury and highlight the pharmacogenomics of such liver insults. Methods for reducing and treating the hepatotoxicity are discussed for specific agents including tamxifen and the newly introduced targeted antibodies.

APA, Harvard, Vancouver, ISO, and other styles

42

Savage, P., C. Holloway, G. Lindsay, K. Shubrook, C. Jones, M. Fung, K. Schaff, H. Anderson, K. Nystedt, and J. Rauw. "Cancer referral and treatment activity 2010–2015: a population-based study from Vancouver Island." Current Oncology 23, no. 6 (December 22, 2016): 626. http://dx.doi.org/10.3747/co.23.3306.

Full text

Abstract:

Introduction The years since 2005 have seen major changes in cancer treatment and significant increases in the number of anticancer drugs available. However, there are relatively few published data to reflect how those changes are affecting the activity and workload of oncology services. To explore the effects of those changes, we reviewed the population-based cancer treatment activity on Vancouver Island for the period 2010–2015.Methods Information about new patient referrals, radiation courses, new chemotherapy cycles commenced, total intravenous (IV) chemotherapy treatment visits, and pharmacy activity for oral anticancer drug prescriptions was obtained from BC Cancer Agency databases.Results During the 5-year study period, the Vancouver Island population increased by 2.8% and the number of new referrals to the BC Cancer Agency increased by 17.7%. The overall number of radiation courses increased by 6.1%. In contrast, IV chemotherapy activity increased by 52.1% for new courses commenced and by 62% for total IV chemotherapy attendances. Oral anticancer drug prescriptions rose by 22.9% during the 5-year period.Conclusions Our study documents substantial recent increases in cancer therapy activity in terms of patient referrals and particularly IV chemotherapy and oral anticancer therapy. The data reported here could be of value in planning for future care provision.

APA, Harvard, Vancouver, ISO, and other styles

43

Yin, Feng, Bobo Gu, Jingxu Li, Nishtha Panwar, Yong Liu, Zigang Li, Ken-Tye Yong, and Ben Zhong Tang. "In vitro anticancer activity of AIEgens." Biomaterials Science 7, no. 9 (2019): 3855–65. http://dx.doi.org/10.1039/c9bm00881k.

Full text

Abstract:

AIEgens possess superior cytotoxicity, tumor invasion, and hemolysis against cancer cells and cancer stem cells. Simple structural modifications enable them as highly biocompatible, image-guided chemotherapy agents.

APA, Harvard, Vancouver, ISO, and other styles

44

Wang, Yan, Wei Xie, Juliette Humeau, Guo Chen, Peng Liu, Jonathan Pol, Zhen Zhang, Oliver Kepp, and Guido Kroemer. "Autophagy induction by thiostrepton improves the efficacy of immunogenic chemotherapy." Journal for ImmunoTherapy of Cancer 8, no. 1 (March 2020): e000462. http://dx.doi.org/10.1136/jitc-2019-000462.

Full text

Abstract:

BackgroundImmunogenic cell death (ICD) is a peculiar modality of cellular demise that elicits adaptive immune responses and triggers T cell-dependent immunity.MethodsFluorescent biosensors were employed for an unbiased drug screen approach aiming at the identification of ICD enhancers.ResultsHere, we discovered thiostrepton as an enhancer of ICD able to boost chemotherapy-induced ATP release, calreticulin exposure and high-mobility group box 1 exodus. Moreover, thiostrepton enhanced anticancer immune responses of oxaliplatin (OXA) in vivo in immunocompetent mice, yet failed to do so in immunodeficient animals. Consistently, thiostrepton combined with OXA altered the ratio of cytotoxic T lymphocytes to regulatory T cells, thus overcoming immunosuppression and reinstating anticancer immunosurveillance.ConclusionAltogether, these results indicate that thiostrepton can be advantageously combined with chemotherapy to enhance anticancer immunogenicity.

APA, Harvard, Vancouver, ISO, and other styles

45

Doundoua, D. P., A. V. Staferov, A. V. Sorokin, and A. G. Kedrova. "CARDIOONCOLOGY: CHEMOTHERAPY DRUGS AND RADIATION THERAPY IMPACT ON CARDIOVASCULAR SYSTEM." Journal of Clinical Practice 7, no. 4 (December 15, 2016): 41–48. http://dx.doi.org/10.17816/clinpract7441-48.

Full text

Abstract:

Anticancer therapy can cause angina pectoris, acute coronary syndrome, stroke, critical limb ischemia, arterial hypertension, arrhythmias and heart failure. The new specialization in cardiology, called cardiooncology, exploring the complications of cardiovascular system, arising during the treatment of cancer. The first part of the review, based on the publications of the last decades, is dedicated to the definition of cardiooncology, mechanisms of cardiac and vascular toxicity with a number of anticancer drugs affecting the cardiovascular system.

APA, Harvard, Vancouver, ISO, and other styles

46

Jiang, Zhi-Gang, Steven A. Fuller, and Hossein A. Ghanbari. "PAN-811 Blocks Chemotherapy Drug-InducedIn VitroNeurotoxicity, While Not Affecting Suppression of Cancer Cell Growth." Oxidative Medicine and Cellular Longevity 2016 (2016): 1–11. http://dx.doi.org/10.1155/2016/9392404.

Full text

Abstract:

Chemotherapy often results in cognitive impairment, and no neuroprotective drug is now available. This study aimed to understand underlying neurotoxicological mechanisms of anticancer drugs and to evaluate neuroprotective effects of PAN-811. Primary neurons in different concentrations of antioxidants (AOs) were insulted for 3 days with methotrexate (MTX), 5-fluorouracil (5-FU), or cisplatin (CDDP) in the absence or presence of PAN-811·Cl·H2O. The effect of PAN-811 on the anticancer activity of tested drugs was also examined using mouse and human cancer cells (BNLT3 and H460) to assess any negative interference. Cell membrane integrity, survival, and death and intramitochondrial reactive oxygen species (ROS) were measured. All tested anticancer drugs elicited neurotoxicity only under low levels of AO and elicited a ROS increase. These results suggested that ROS mediates neurotoxicity of tested anticancer drugs. PAN-811 dose-dependently suppressed increased ROS and blocked the neurotoxicity when neurons were insulted with a tested anticancer drug. PAN-811 did not interfere with anticancer activity of anticancer drugs against BNLT3 cells. PAN-811 did not inhibit MTX-induced death of H460 cells but, interestingly, demonstrated a synergistic effect with 5-FU or CDDP in reducing cancer cell viability. Thus, PAN-811 can be a potent drug candidate for chemotherapy-induced cognitive impairment.

APA, Harvard, Vancouver, ISO, and other styles

47

Sheng Sow, Heng, and Stephen R. Mattarollo. "Combining low-dose or metronomic chemotherapy with anticancer vaccines." OncoImmunology 2, no. 12 (December 2013): e27058. http://dx.doi.org/10.4161/onci.27058.

Full text

APA, Harvard, Vancouver, ISO, and other styles

48

Gohji, Kazuo, and Sadao Kamidono. "STUDY OF ANTICANCER CHEMOTHERAPY FOR HUMAN RENAL CELL CARCINOMA." Japanese Journal of Urology 78, no. 6 (1987): 982–90. http://dx.doi.org/10.5980/jpnjurol1928.78.6_982.

Full text

APA, Harvard, Vancouver, ISO, and other styles

49

Focher, F., and S. Spadari. "Thymidine Phosphorylase: A Two-Face Janus in Anticancer Chemotherapy." Current Cancer Drug Targets 1, no. 2 (August 1, 2001): 141–53. http://dx.doi.org/10.2174/1568009013334232.

Full text

APA, Harvard, Vancouver, ISO, and other styles

50

Nakashima, Makoto, Takuya Goto, Sachika Maeta, Mie Nomura, Yukiko Shibata, Kimio Wakabayashi, Hiromitsu Kato, et al. "Development of Anticancer Chemotherapy Support Software and Its Evaluation." Iryo Yakugaku (Japanese Journal of Pharmaceutical Health Care and Sciences) 37, no. 12 (2011): 721–27. http://dx.doi.org/10.5649/jjphcs.37.721.

Full text

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!